Clinical Trial

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-09.
Status change: Not Yet Recruiting → Recruiting 2024-08-19
Trial Details
NCT Number NCT06176534
Lead Sponsor Henan Cancer Hospital
Conditions Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
Enrollment 240 participants
Start Date 2024-01-01
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2024-08-20